Last reviewed · How we verify
LCB01-0371 800mg, QD — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
LCB01-0371 800mg, QD (LCB01-0371 800mg, QD) — LigaChem Biosciences, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LCB01-0371 800mg, QD TARGET | LCB01-0371 800mg, QD | LigaChem Biosciences, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LCB01-0371 800mg, QD CI watch — RSS
- LCB01-0371 800mg, QD CI watch — Atom
- LCB01-0371 800mg, QD CI watch — JSON
- LCB01-0371 800mg, QD alone — RSS
Cite this brief
Drug Landscape (2026). LCB01-0371 800mg, QD — Competitive Intelligence Brief. https://druglandscape.com/ci/lcb01-0371-800mg-qd. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab